Comparison

tenofovir-alafenamide-hemifumarate

Manufacturer InvivoChem LLC
Category
Type Biochemicals
Specific against other
Amount 250mg
Item no. V16064-250mg
CASRN 1392275-56-7
eClass 6.1 32160405
eClass 9.0 32160490
Available
Description
InvivoChem Cat #:V16064CAS #:1392275-56-7Purity >=98%

Description:Tenofovir Alafenamide hemifumarate (formerly also known as TAF and GS-7340) is anovel prodrug of tenofovir, which is a potent reverse transcriptaseinhibitor nucleotide reverse transcriptase inhibitor (NRTIs), it isused for the treatment of HIV and Hepatitis B. By blocking reversetranscriptase, Tenofovir Alafenamide prevent HIV from multiplying andcan reduce the amount of HIV in the body. Tenofovir alafenamide is aprodrug that it is inactive in the parent form, and has to be convertedto tenofovir diphosphate (TFV-DP) in vivo.

References: Nucleosides Nucleotides Nucleic Acids. 2001; 20:1085-90; Antimicrob Agents Chemother. 2005; 49:1898-906.

Related CAS#: 147127-20-6(Tenofovir); 202138-50-9 (fumarate); 206184-49-8 (hydrate); 206184-49-8(hydrate); 1571075-19-8 (aspartate); 201341-05-1 Tenofovir dsoproxil); 1236287-04-9 (Tenofovir maleate); 1392275-56-7 (Tenofovir alafenamidehemifumarate); 379270-38-9 (Tenofovir alafenamide fumarate); 1464851-21-5 (Z)-9-Propenyladenine; (Z)-Mutagenic Impurity of TenofovirDisoproxil; 1446486-33-4 9-Propenyladenine; Mutagenic Impurity ofTenofovir Disoproxil; Tenofovir Impurity 2; 1276030-80-8(Tenofovir disoproxil maleate) 1453166-76-1 (Tenofovir disoproxilphosphate) 1637632-97-3 (Tenofovir disoproxil succinate)

Description:Tenofovir Alafenamide hemifumarate (formerly also known as TAF and GS-7340) is anovel prodrug of tenofovir, which is a potent reverse transcriptaseinhibitor nucleotide reverse transcriptase inhibitor (NRTIs), it isused for the treatment of HIV and Hepatitis B. By blocking reversetranscriptase, Tenofovir Alafenamide prevent HIV from multiplying andcan reduce the amount of HIV in the body. Tenofovir alafenamide is aprodrug that it is inactive in the parent form, and has to be convertedto tenofovir diphosphate (TFV-DP) in vivo.

References: Nucleosides Nucleotides Nucleic Acids. 2001; 20:1085-90; Antimicrob Agents Chemother. 2005; 49:1898-906.

Related CAS#: 147127-20-6(Tenofovir); 202138-50-9 (fumarate); 206184-49-8 (hydrate); 206184-49-8(hydrate); 1571075-19-8 (aspartate); 201341-05-1 Tenofovir dsoproxil); 1236287-04-9 (Tenofovir maleate); 1392275-56-7 (Tenofovir alafenamidehemifumarate); 379270-38-9 (Tenofovir alafenamide fumarate); 1464851-21-5 (Z)-9-Propenyladenine; (Z)-Mutagenic Impurity of TenofovirDisoproxil; 1446486-33-4 9-Propenyladenine; Mutagenic Impurity ofTenofovir Disoproxil; Tenofovir Impurity 2; 1276030-80-8(Tenofovir disoproxil maleate) 1453166-76-1 (Tenofovir disoproxilphosphate) 1637632-97-3 (Tenofovir disoproxil succinate)

1276030-80-8(Tenofovir disoproxil maleate) 1453166-76-1 (Tenofovir disoproxilphosphate) 1637632-97-3 (Tenofovir disoproxil succinate)

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 250mg
Available: In stock
available

Delivery expected until 6/6/2024 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close